GlassScriptPhysician profile
Marcellus Lahaye
NPI 1073584744
$2,813.03
in general payments reported to CMS, 2019-2025
40 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $489 · 2021: $638 · 2022: $306 · 2023: $389 · 2024: $391 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $642.37 | 2023-2025 | Gemtesa, Orgovyx |
| Neotract INC. | $370.31 | 2019-2020 | |
| Janssen Biotech, INC. | $176.60 | 2020-2021 | |
| Astellas Pharma US INC | $167.36 | 2021-2023 | Veozah, Xtandi |
| Sunovion Pharmaceuticals INC. | $137.41 | 2021-2022 | |
| Abbvie INC. | $125.66 | 2019-2024 | |
| Pfizer INC. | $100.62 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.36 | 2019-2021 | |
| Novo Nordisk INC | $96.81 | 2019-2024 | Ozempic, Rybelsus |
| Cardiovascular Systems INC. | $78.08 | 2021 | |
| Urovant Sciences INC | $77.00 | 2021-2022 | |
| Boston Scientific Corporation | $72.37 | 2020-2023 | |
| Urogen Pharma, INC. | $57.10 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $56.57 | 2019-2022 | |
| Amgen INC. | $46.83 | 2021-2025 | Otezla, Repatha, Otezla |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcellus Lahaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.